Explaining the in vitro and in vivo differences in leukemia therapy

Cell Cycle

Volumn 10, Issue 10, 2011, Pages 1540-1544

  Lenaerts, Tom ^a,b   Castagnetti, Fausto ^c   Traulsen, Arne ^d   Pacheco, Jorge M ^e,f   Rosti, Gianantonio ^c   Dingli, David ^g  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY   (Germany)

^e UNIVERSITY OF MINHO   (Portugal)

^f UNIVERSITY OF LISBON   (Portugal)

^g Mayo Clinic   (United States)

Author keywords

Evolution; Hematopoiesis; Reproductive fitness; Selection; Self renewal

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB;

APOPTOSIS; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CD34 SELECTION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; REVIEW; TREATMENT RESPONSE;

EID: 79956043299     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.10.15518     Document Type: Review

References (34)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17. (Pubitemid 44903745)
2. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145:913-23. (Pubitemid 351639967)
3. Luzzatto L, Melo JV. Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. Blood 2002; 100:1105. (Pubitemid 34832656)
4. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100:1014-8. (Pubitemid 34832631)
5. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinibresistant chronic myeloid leukaemia. Nat Rev 2007; 7:345-56. (Pubitemid 46652483)
6. + CML cells. Blood 2007.
7. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22:748-55. (Pubitemid 351552624)
8. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114:4933-8.
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010.
10. Lenaerts T, Pacheco JM, Traulsen A, Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 2010; 95:900-7.
11. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12:1181-4. (Pubitemid 44527354)
12. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
13. Marley SB, Davidson RJ, Goldman JM, Gordon MY. Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol 2002; 116:162-5. (Pubitemid 34122075)
14. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-25. (Pubitemid 41039112)
15. Dingli D, Traulsen A, Michor F. (A)Symmetric stem cell replication and cancer. PLoS Comput Biol 2007; 3:53.
16. Traulsen A, Pacheco JM, Dingli D. Reproductive fitness advantage of BCR-ABL expressing leukemia cells. Cancer Letters 2010; 294:43-8.
17. Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000; 28:551-7. (Pubitemid 30254456)
18. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66:10959-66. (Pubitemid 44876995)
19. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL and EGF receptor oncogenes. Cancer Cell 2006; 10:425-35.
20. Schemionek M, Elling C, Steidl U, Baumer N, Hamilton A, Spieker T, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010; 115:3185-95.
21. Dingli D, Traulsen A, Pacheco JM. Chronic myeloid leukemia: origin, development, response to therapy and relapse. Clinical Leukemia 2008; 2:133-9.
22. Dingli D, Traulsen A, Lenaerts T, Pacheco JM. Evolutionary dynamics of chronic myeloid leukemia. Genes Cancer 2010; 1:309-15.
23. Marley SB, Gordon MY. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin Sci 2005; 109:13-25. (Pubitemid 40943029)
24. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010.
25. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. E Enlg J Med 2004; 351:657-67. (Pubitemid 39063268)
26. Dingli D, Traulsen A, Pacheco JM. Compartmental architecture and dynamics of hematopoiesis. PLoS ONE 2007; 2:345.
27. Gordon MY, Blackett NM. Routes to repopulation - a unification of the stochastic model and separation of stem-cell subpopulations. Leukemia 1994; 8:1068-72.
28. Abkowitz JL, Catlin SN, Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med 1996; 2:190-7. (Pubitemid 26054982)
29. Donohue DM, Reiff RH, Hanson ML, Betson Y, Finch CA. Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. J Clin Invest 1958; 37:1571-6.
30. Cronkite EP, Fliedner TM. Granulocytopoiesis. The New England journal of medicine 1964; 270:1347 52.
31. Finch CA, Harker LA, Cook JD. Kinetics of the formed elements of human blood. Blood 1977; 50:699-707. (Pubitemid 8194897)
32. Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 2002; 16:549-58. (Pubitemid 34449732)
33. Ichimaru M, Ishimaru T, Mikami M, Yamada Y, Ohkita T. Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki October 1950-December 1978: Technical Report RERF TR 13-81. Hiroshima: Radiation Effects Research Foundation 1981.
34. Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010; 107:16280-5.